Targeting inflammatory pathways for treatment of major depressive disorder.

Publication date: Jul 06, 2023

Current treatments modalities for major depressive disorder (MDD) mainly target monoaminergic neurotransmission. However, the therapeutic inadequacy and adverse effects confine the use of these conventional antidepressants to a limited subset of patients with MDD. Classic antidepressants are increasingly proving unsatisfactory in tackling treatment-resistant depression (TRD). Hence, the focus of treatment is shifting to alternative pathogenic pathways involved in depression. Preclinical and clinical evidence unequivocally affirmed the causative role of immuno-inflammatory pathways in the progression of depression, resulting in an increase in the clinical evaluation of drugs with anti-inflammatory effects being used as antidepressants. In this review, we highlight the molecular mechanisms connecting inflammatory pathways to MDD and the current clinical status of inflammation-modulating drugs for the treatment of MDD.

Concepts Keywords
Antidepressants astrocytes
Discov depression
Molecular inflammation
Target kinins
Unsatisfactory TNF-α


Type Source Name
disease MESH major depressive disorder
disease MESH inflammation

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *